Premaitha Health PLC (LON:NIPT)‘s stock had its “corporate” rating reissued by equities researchers at FinnCap in a report released on Tuesday.
Shares of Premaitha Health PLC (LON NIPT) opened at GBX 7.88 ($0.10) on Tuesday. Premaitha Health PLC has a 52 week low of GBX 6.85 ($0.09) and a 52 week high of GBX 14.40 ($0.19).
COPYRIGHT VIOLATION WARNING: “Premaitha Health PLC (NIPT) Stock Rating Reaffirmed by FinnCap” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/11/21/premaitha-health-plc-nipt-stock-rating-reaffirmed-by-finncap.html.
About Premaitha Health PLC
Premaitha Health PLC is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The Company’s product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house.
Receive News & Ratings for Premaitha Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Premaitha Health PLC and related companies with MarketBeat.com's FREE daily email newsletter.